Simulations Plus Inc
Research Simulations Plus Inc (SLP) on Bullrun: valuation model: 19.4% overvalued, market cap USD 374.00M, P/E 46.2. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerSLP
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryHealth Information Services
- CurrencyUSD
- Valuation signal19.4% overvalued
- Market capUSD 374.00M
- P/E46.2
- Financial periodQ2 2026
- RevenueUSD 21.89M
- Net incomeUSD 3.58M
- Free cash flowUSD 7.95M
- Gross margin69.1%
Valuation Snapshot
Bullrun's latest valuation model marks Simulations Plus Inc as 19.4% overvalued; latest market cap is USD 374.00M; P/E is 46.2.
Peer valuation comparison
Latest P/E is 46.23x versus a Healthcare sector median of 24.61x (87.9% above).
Latest P/E is 46.23x versus a United States median of 23.85x (93.8% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 79.18M | -USD 64.72M | USD 17.41M | 58.4% | -3.22 | USD 30.85M | USD 616.00K | USD 124.80M |
| FY2024 | USD 70.01M | USD 9.95M | USD 12.75M | 61.6% | 0.49 | USD 10.31M | USD 1.01M | USD 182.43M |
| FY2023 | USD 59.58M | USD 9.96M | USD 21.40M | 80.5% | 0.49 | USD 57.52M | USD 1.20M | USD 170.03M |
| FY2022 | USD 53.91M | USD 12.48M | USD 17.08M | 79.9% | 0.6 | USD 51.57M | USD 1.40M | USD 178.25M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-07 | USD 374.00M | 46.2 | n/a | n/a |
| 2025 | 2025-12-31 | USD 367.27M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 560.38M | 69.7 | 0.6% | 0.18 |
| 2023 | 2023-12-29 | USD 893.53M | 86.1 | 0.5% | 0.24 |
| 2022 | 2022-12-30 | USD 743.45M | 70.3 | 0.7% | 0.24 |
| 2021 | 2021-12-31 | USD 953.98M | 94.6 | 0.5% | 0.24 |
Dividend history
| Year | Dividends/share |
|---|---|
| FY2024 | 0.24 USD |
| FY2023 | 0.24 USD |
| FY2022 | 0.24 USD |
About Simulations Plus Inc
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through Software and Services segments. The company offers GastroPlus, which predicts absorption, biopharmaceutics, pharmacokinetics, and pharmacodynamics in humans and animals; and DDDPlus and MembranePlus simulation products.
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Simulations Plus Inc overvalued or undervalued?
Bullrun's valuation model currently marks Simulations Plus Inc as 19.4% overvalued.
What is Simulations Plus Inc's market cap?
Simulations Plus Inc's market capitalization is USD 374.00M.
What is Simulations Plus Inc's P/E ratio?
Simulations Plus Inc's price-to-earnings (P/E) ratio is 46.2.
What does Simulations Plus Inc do?
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through Software and Services segments. The company offers GastroPlus, which predicts absorption, biopharmaceutics, pharmacokinetics, and pharmacodynamics in humans and animals; and DDDPlus and MembranePlus simulation products.